MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the fourth quarter and full year 2024, highlighting significant business progress and clinical advancements. The company will host a conference call and webcast at 8:30 a.m. ET.
'Throughout 2024, MiNK advanced its mission to bring off-the-shelf iNKT cell therapies to patients fighting hard-to-treat cancers and severe immune-related disorders,' said Dr. Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics. 'We made significant clinical strides, strengthened our manufacturing foundation, and forged strategic alliances. Through disciplined capital management, we are positioned to scale efficiently and seize new collaboration opportunities for value creation. With our rapid AI-driven drug discovery platform generating a world-class library of phosphorylated neoantigens and proprietary TCRs, MiNK is uniquely poised to progress a new standard in oncology and beyond.'
Operational Highlights
Clinical Advancements
Expanding Benefit in Where Standards Fail: Presentations at leading oncology conferences—including AACR IO, ASCO GI, and SITC—demonstrated that AgenT-797 enhanced immune activation, improved checkpoint inhibitor efficacy, and augmented bispecific engagers in heavily pretreated patients and preclinical models. A Phase 2 Investigator-Sponsored Trial (Memorial Sloan Kettering Cancer Center) in second-line advanced gastric cancer (NCT06251973) is actively enrolling. Early data suggest promising activity when combining AgenT-797 with botensilimab/balstilimab (BOT/BAL) and chemotherapy.
Immunologic Activity in Inflammatory Lung Conditions (): Published results in Nature Communications and presented at the American Thoracic Society (ATS) showed AgenT-797's potential in acute respiratory distress, with an approximately 80% survival rate among VV ECMO patients versus 10% in hospital controls. Late-stage trials are designed and planned for upcoming discussion with the regulatory agencies.
Next-Generation iNKT Programs
PRAME-TCR iNKTs: Demonstrated high specificity and potent tumor-killing against intracellular cancer targets resistant to conventional therapies. MiNK's expertise in accessing a proprietary library of phosphorylated peptides and personalized neoantigens supports the generation of high-quality TCRs.
MiNK-215 (IL-15 Armored CAR-iNKT): Robust anti-tumor activity in models of metastatic colorectal cancer, reshaping the immunosuppressive tumor microenvironment.
These data, including exciting findings from AACR IO on the importance of neoantigen targeting, underscore MiNK's commitment to evolving next-generation iNKT treatments that could potentially tackle the most challenging cancer types.
Strategic Growth and Manufacturing Optimization
MiNK's state-of-the-art manufacturing process enables the production of billions of donor-derived iNKT cells per run, scalable to support rapid global distribution, aimed at reducing logistical hurdles, cost, and enhancing patient access.
In October 2024, MiNK entered into a research collaboration with Autonomous Therapeutics to develop precision RNA-iNKT therapies for metastatic tumors. This collaboration is actively underway.
In 2024, MiNK raised $5.8M in private financing and is prioritizing externally funded clinical trials to effectively sustain and advance its iNKT cell programs.
'We believe MiNK Therapeutics is on solid footing to pioneer the next generation of cell therapies,' added Dr. Buell. 'We will continue to pair scientific discipline with operational rigor, a strategy designed to enable value-inflection in 2025 and beyond.'
Financial Highlights
We ended the year with a cash balance of $4.6 million. Cash used in operations for the three and twelve months ended December 31, 2024, was $1.7 million, and $9.6 million, respectively, compared to $3.0 million and $15.8 million for the same periods in 2023.
Net loss for the year ended December 31, 2024 was $10.8 million, or $2.86 per share, compared to net loss for the same period in 2023 of $22.5 million or $6.54 per share.
Summary Consolidated Financial Information
Condensed Consolidated Balance Sheet Data
(in thousands)
(unaudited)
December 31,
2024
2023
Cash and cash equivalents
$
4,577
$
3,367
Total assets
5,721
4,552
Other Financial Information
(in thousands)
(unaudited)
Three months ended December 31,
Year ended December 31,
2024
2023
2024
2023
Cash used in operations
$
1,728
$
3,036
$
9,555
$
15,763
Non-cash expenses
757
1,155
770
3,798
Condensed Consolidated Statements of Operations Data
(in thousands, except per share data)
(unaudited)
Three months ended December 31,
Year ended December 31,
2024
2023
2024
2023
Operating expenses:
Research and development
$
1,406
$
3,311
$
6,336
$
15,490
General and administrative
809
2,189
4,314
7,431
Change in fair value of related party note
288
-
638
-
Operating loss
2,503
5,500
11,288
22,921
Other income, net
(39
)
(41
)
(503
)
(463
)
Net loss
$
2,464
$
5,459
$
10,785
$
22,458
Per common share data, basic and diluted:
Net loss
$
0.62
$
1.58
$
2.86
$
6.54
Weighted average number of common shares outstanding, basic and diluted
3,957
3,456
3,773
3,436
Conference Call
Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada)
Conference ID: 8023784
Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company's website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/s9hd6k7m/.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
About AgenT-797
AgenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy that harnesses the dual power of innate and adaptive immunity. iNKTs function as 'master regulators,' combining the cytotoxic capabilities of NK cells with T-cell–like antigen recognition and memory. This unique biology enables a robust, pathogen-agnostic immune response that can be directed against hard-to-treat tumors.
Manufactured by MiNK Therapeutics in Lexington, MA, agenT-797 is a scalable, off-the-shelf product designed to provide accessible, transformative treatment options. In clinical trials, agenT-797 can bolster peripheral memory T-cell activation, enhance tumor infiltration, and potentially improve outcomes for patients with solid cancers (Cytryn et al. AACR IO 2024, Oncogene. 2024) and to combat inflammation in critically ill patients with severe respiratory pathology (Nature Communications. 2024).
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells, as well as the collaboration between MiNK and Agenus. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Agenus with no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact
917-362-1370
investor@minktherapeutics.com
Media Contact
781-674-4428
communications@minktherapeutics.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Why Casey's General Stores Stock Skyrocketed This Week
Casey's General Stores is quietly the fifth-largest pizza chain in the United States. It continues to grow its geographic footprint beyond the Midwest, and is now in 20 states. Leaning on its ability to make shrewd acquisitions, Casey's growth story could still be in its early chapters. 10 stocks we like better than Casey's General Stores › Shares of Midwestern pizza and convenience store chain Casey's General Stores (NASDAQ: CASY) were 13% higher this week as of 12:30 p.m. ET Thursday, according to data provided by S&P Global Market Intelligence. Reporting fourth-quarter earnings, Casey's delivered earnings before interest, taxes, depreciation, and amortization (EBITDA) and earnings per share growth of 20% and 12%, surpassing analysts' expectations. This booming profitability, paired with management's announcement of a 14% dividend increase, sent Casey's shares skyward. Casey's General Stores operates approximately 2,900 locations, primarily located in small towns across the Midwest. As it expanded beyond its roots in Iowa to its current footprint of 20 states, the company has become a 258-bagger since 1990. Despite this incredible run, I recently wrote that Casey's is still an excellent long-term buy -- despite nearing all-time highs. And again, I'd argue it still looks pretty promising even after this week's run-up. Growing its store count by 9% in 2025, management's expansion plans show no signs of slowing. Powered by its mergers and acquisitions team, Casey's has been expanding into new states, like Texas, Tennessee, and Florida. The reason this M&A model works so well is that Casey's typically focuses on buying convenience stores without a strong food presence. Then it adds a Casey's kitchen, bringing in its beloved pizza-making and prepared food capabilities to these new locations, boosting profitability and generating a strong return on its investment. However, even with its recent success, the company's valuation remains reasonable at 17 times cash from operations (CFO). For example, whereas Casey's has grown its net income by 19% annually over the last decade, Domino's Pizza has only grown its profits by 14% over the same time, yet trades at 23 times CFO. Before you buy stock in Casey's General Stores, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Casey's General Stores wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,871!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $875,479!* Now, it's worth noting Stock Advisor's total average return is 998% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Josh Kohn-Lindquist has positions in Casey's General Stores. The Motley Fool has positions in and recommends Domino's Pizza. The Motley Fool recommends Casey's General Stores. The Motley Fool has a disclosure policy. Why Casey's General Stores Stock Skyrocketed This Week was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
KBW Announces Index Rebalancing for Second-Quarter 2025
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Keefe, Bruyette & Woods, Inc., a leading specialist investment bank to the financial services and fintech sectors, and a wholly owned subsidiary of Stifel Financial Corp. (NYSE: SF), announces the upcoming index rebalancing for the second quarter of 2025. This quarter, there are constituent changes within one of our indexes: KBW Nasdaq Premium Yield Equity REIT Index (Index Ticker: KYX, ETF Ticker: KBWY). These changes will be effective prior to the opening of business on Monday, June 23, 2025. As part of this rebalancing, below are the component-level changes across impacted indices: KBW Nasdaq Premium Yield Equity REIT Index (Index Ticker: KYX; ETF Ticker: KBWY) Drop (1): SITE Centers Corp. (NYSE: SITC) Several of the KBW Nasdaq indexes have tradable exchange‐traded funds licensed: KBW Nasdaq Bank Index (Index Ticker: BKXSM, ETF Ticker: KBWBSM); KBW Nasdaq Capital Markets Index (Index Ticker: KSXSM); KBW Nasdaq Insurance Index (Index Ticker: KIXSM); KBW Nasdaq Regional Banking Index (Index Ticker: KRXSM, ETF Ticker: KBWRSM); KBW Nasdaq Financial Sector Dividend Yield Index (Index Ticker: KDXSM, ETF Ticker: KBWDSM); KBW Nasdaq Premium Yield Equity REIT Index (Index Ticker: KYXSM, ETF Ticker: KBWYSM); KBW Nasdaq Property and Casualty Insurance Index (Index Ticker: KPXSM, ETF Ticker: KBWPSM); KBW Nasdaq Global Bank Index (Index Ticker: GBKXSM); KBW Nasdaq Financial Technology Index (Index Ticker: KFTXSM, ETF Ticker: Not all of the listed securities may be suitable for retail investors; in addition, not all of the listed securities may be available to U.S. investors. European investors interested in FTEK LN can contact Invesco at U.S. investors cannot buy or hold FTEK LN. An investor cannot invest directly in an index. About KBW KBW (Keefe, Bruyette & Woods, Inc., operating in the U.S., and Stifel Nicolaus Europe Limited, also trading as Keefe, Bruyette & Woods Europe, operating in Europe) is a Stifel company. Over the years, KBW has established itself as a leading independent authority in the banking, insurance, brokerage, asset management, mortgage banking and specialty finance sectors. Founded in 1962, the firm maintains industry‐leading positions in the areas of research, corporate finance, mergers and acquisitions as well as sales and trading in equities securities of financial services companies. Media Contact Neil Shapiro, (212) 271-3447shapiron@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Michiganders are returning fewer bottles and cans. Why?
GRAND RAPIDS, Mich. (WOOD) — The value of a dime doesn't stretch as far as it did in 1976 when the state's bottle deposit law was initiated, but for many Michiganders, returning beverage containers to get their 10 cents back sure adds up. 'I don't want to throw my pennies and dimes away,' Grand Rapids resident Mildred Griffin said. 'The cost of living is so high right now. You would be a fool to throw away 10 cents.' For Griffin, returning bottles and cans is a way of life. She said it's like getting paid to recycle. She was surprised to learn that fewer people are turning in their bottles to get that dime back. Statewide return rates have fallen to their lowest point. In 2024, just over 70% of bottles and cans were returned. Workers at a number of local markets told News 8 they have seen fewer returns in recent years. At Kingma's Market in Grand Rapids, owner Alan Hartline said the redemption process adds complications to store owners. He said the process, from collecting to sorting, is in serious need of an update. 'It really taxes the supply chain and adds a lot of cost to it for businesses,' he said, 'I think there can be a better way to facilitate it. It should be earth friendly, but perhaps to do it without the cost and as many hoops as the current process today.' Sen. Sean McCann, D-Kalamazoo, also believes there's a need for change, including an expansion. 'Even though we've come off our highs, habits have changed, there's a real ability to still improve our system and make it get better,' he said. McCann reintroduced a bill to modify the bottle return law to include other containers, primarily plastic water bottles. 'I think it's terrible that we have over 2 billion plastic water bottles that don't necessarily get recycled and often get landfilled and are not eligible for the deposit,' he said. He's also pushing for bottles and cans to be returnable anywhere — not just at chains that carry the brands being returned. He said that is part of the reason the rates are dropping. 'Part of the bugaboo is a universal redemption,' he said. 'You buy something at one store (but) you can't take it back to the other store.' For McCann, the goal is to get the issue on the ballot and let the citizens decide. 'This is not something worth giving up on for me,' he said. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
